JP6646282B2 - 多発性硬化症のためのａａｖ系遺伝子療法 - Google Patents

多発性硬化症のためのａａｖ系遺伝子療法 Download PDF

Info

Publication number
JP6646282B2
JP6646282B2 JP2016564019A JP2016564019A JP6646282B2 JP 6646282 B2 JP6646282 B2 JP 6646282B2 JP 2016564019 A JP2016564019 A JP 2016564019A JP 2016564019 A JP2016564019 A JP 2016564019A JP 6646282 B2 JP6646282 B2 JP 6646282B2
Authority
JP
Japan
Prior art keywords
nucleic acid
raav
protein
mog
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016564019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513500A (ja
JP2017513500A5 (enExample
Inventor
ブラッド・イー・ホフマン
Original Assignee
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド, ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド filed Critical ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド
Publication of JP2017513500A publication Critical patent/JP2017513500A/ja
Publication of JP2017513500A5 publication Critical patent/JP2017513500A5/ja
Priority to JP2019235107A priority Critical patent/JP7430898B2/ja
Application granted granted Critical
Publication of JP6646282B2 publication Critical patent/JP6646282B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2016564019A 2014-04-24 2015-04-24 多発性硬化症のためのａａｖ系遺伝子療法 Active JP6646282B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019235107A JP7430898B2 (ja) 2014-04-24 2019-12-25 多発性硬化症のためのａａｖ系遺伝子療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461983924P 2014-04-24 2014-04-24
US61/983,924 2014-04-24
PCT/US2015/027598 WO2015164789A1 (en) 2014-04-24 2015-04-24 Aav-based gene therapy for multiple sclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019235107A Division JP7430898B2 (ja) 2014-04-24 2019-12-25 多発性硬化症のためのａａｖ系遺伝子療法

Publications (3)

Publication Number Publication Date
JP2017513500A JP2017513500A (ja) 2017-06-01
JP2017513500A5 JP2017513500A5 (enExample) 2018-07-26
JP6646282B2 true JP6646282B2 (ja) 2020-02-14

Family

ID=54333299

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016564019A Active JP6646282B2 (ja) 2014-04-24 2015-04-24 多発性硬化症のためのａａｖ系遺伝子療法
JP2019235107A Active JP7430898B2 (ja) 2014-04-24 2019-12-25 多発性硬化症のためのａａｖ系遺伝子療法
JP2022031064A Pending JP2022081549A (ja) 2014-04-24 2022-03-01 多発性硬化症のためのａａｖ系遺伝子療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019235107A Active JP7430898B2 (ja) 2014-04-24 2019-12-25 多発性硬化症のためのａａｖ系遺伝子療法
JP2022031064A Pending JP2022081549A (ja) 2014-04-24 2022-03-01 多発性硬化症のためのａａｖ系遺伝子療法

Country Status (17)

Country Link
US (3) US20170043036A1 (enExample)
EP (2) EP3744177A1 (enExample)
JP (3) JP6646282B2 (enExample)
AU (2) AU2015249328B2 (enExample)
CA (1) CA2945984C (enExample)
CY (1) CY1123312T1 (enExample)
DK (1) DK3133923T3 (enExample)
ES (1) ES2814280T3 (enExample)
HR (1) HRP20201342T1 (enExample)
HU (1) HUE050681T2 (enExample)
LT (1) LT3133923T (enExample)
PL (1) PL3133923T3 (enExample)
PT (1) PT3133923T (enExample)
RS (1) RS60816B1 (enExample)
SI (1) SI3133923T1 (enExample)
SM (1) SMT202000453T1 (enExample)
WO (1) WO2015164789A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7270946B2 (ja) * 2017-08-08 2023-05-11 国立大学法人浜松医科大学 自己免疫疾患の治療又は予防剤
JP2021533805A (ja) * 2018-08-24 2021-12-09 スパーク セラピューティクス インコーポレイテッドSpark Therapeutics, Inc. 最適化されたプロモーター配列、イントロンを含まない発現構築物及び使用方法
AU2020289326A1 (en) * 2019-06-04 2022-01-27 Thomas Jefferson University Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
US20230263909A1 (en) * 2020-04-14 2023-08-24 University Of Florida Research Foundation, Incorporated Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis
EP4135777A4 (en) * 2020-04-14 2025-03-12 University Of Florida Research Foundation, Incorporated AAV-BASED GENE THERAPIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CN116209477A (zh) * 2020-06-30 2023-06-02 儿童国家医疗中心 使用重组人酸性鞘氨醇酶改善骨骼肌纤维的修复
WO2024081570A1 (en) * 2022-10-10 2024-04-18 Eli Lilly And Company Methods and systems for using causal networks to develop models for evaluating biological processes
WO2024258925A1 (en) 2023-06-12 2024-12-19 Children's Hospital Medical Center Aav-cftr vectors and methods of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7725894A (en) * 1993-09-03 1995-03-22 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1998024479A1 (en) * 1996-12-02 1998-06-11 Cell Genesys, Inc. Adeno-associated viral vector-mediated delivery of dna to cells of the liver
ATE270306T1 (de) * 2000-10-02 2004-07-15 Univ Yonsei Seoul Einkettige insulinanaloge
KR100449454B1 (ko) * 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
CA2361462A1 (en) * 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
WO2003104413A2 (en) 2002-06-05 2003-12-18 University Of Florida Production of pseudotyped recombinant aav virions
WO2007094003A2 (en) * 2006-02-15 2007-08-23 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
US20120322861A1 (en) 2007-02-23 2012-12-20 Barry John Byrne Compositions and Methods for Treating Diseases
US9938540B2 (en) * 2008-11-12 2018-04-10 Ospedale San Raffaele S.R.L. Gene vector for inducing transgene-specific immune tolerance
US9402919B2 (en) * 2011-03-04 2016-08-02 Intrexon Corporation Vectors conditionally expressing protein
EP2760478A1 (en) * 2011-09-26 2014-08-06 Universität Zürich Prorektorat MNW Apc-mediated tolerance induction for therapy of multiple sclerosis
ES2719691T3 (es) * 2013-11-22 2019-07-12 Amarna Holding B V Procedimiento de restauración de tolerancia inmunitaria in vivo
EP4135777A4 (en) * 2020-04-14 2025-03-12 University Of Florida Research Foundation, Incorporated AAV-BASED GENE THERAPIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Also Published As

Publication number Publication date
SMT202000453T1 (it) 2020-09-10
EP3133923A4 (en) 2017-12-27
EP3133923B1 (en) 2020-06-03
AU2015249328A1 (en) 2016-10-27
LT3133923T (lt) 2020-08-25
AU2019202958A1 (en) 2019-05-16
PT3133923T (pt) 2020-09-04
CA2945984A1 (en) 2015-10-29
JP2017513500A (ja) 2017-06-01
CA2945984C (en) 2023-09-26
PL3133923T3 (pl) 2021-02-22
HUE050681T2 (hu) 2020-12-28
AU2015249328B2 (en) 2019-01-17
DK3133923T3 (da) 2020-08-10
HRP20201342T1 (hr) 2020-11-27
US20230381342A1 (en) 2023-11-30
EP3133923A1 (en) 2017-03-01
JP2020062038A (ja) 2020-04-23
CY1123312T1 (el) 2021-12-31
WO2015164789A1 (en) 2015-10-29
ES2814280T3 (es) 2021-03-26
SI3133923T1 (sl) 2020-11-30
JP7430898B2 (ja) 2024-02-14
US20170043036A1 (en) 2017-02-16
RS60816B1 (sr) 2020-10-30
EP3744177A1 (en) 2020-12-02
US20200138978A1 (en) 2020-05-07
JP2022081549A (ja) 2022-05-31
AU2019202958B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
JP7430898B2 (ja) 多発性硬化症のためのａａｖ系遺伝子療法
AU2019200949B2 (en) High-transduction-efficiency raav vectors, compositions, and methods of use
US20180244727A1 (en) Capsid-modified raav vector compositions having improved transduction efficiencies, and methods of use
AU2020200041A1 (en) Capsid-modified, rAAV3 vector compositions and uses in gene therapy of human liver cancer
US20150133530A1 (en) High-transduction-efficiency raav vectors, compositions, and methods of use
KR20160035596A (ko) 뇌 질환을 치료하기 위한 방법 및 조성물
US12297444B2 (en) AAV-based gene therapies for treatment of autoimmune diseases
US20230263909A1 (en) Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis
HK40041411A (en) Aav-based gene therapy for multiple sclerosis
HK1234606A1 (en) Aav-based gene therapy for multiple sclerosis
HK1234606B (en) Aav-based gene therapy for multiple sclerosis
HK1208683B (en) High-transduction-efficiency raav vectors, compositions, and methods of use

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190611

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191225

R150 Certificate of patent or registration of utility model

Ref document number: 6646282

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250